Management of Chronic Kidney Disease Stages 1–3
Factors That Impact Potential Benefit of Screening Adults for CKD Stages 1–3
Factors that impact the potential benefit of screening adults for chronic kidney disease (CKD) stages 1–3 include: (1) whether undiagnosed CKD is sufficiently prevalent in the population overall or in certain high-risk groups; (2) whether CKD is associated with significant adverse health consequences and/or health care costs; (3) whether CKD is accurately diagnosable while asymptomatic; (4) whether there are valid and reliable screening tests for CKD that are acceptable to patients and available in primary care settings; and (5) whether there are treatments for patients with CKD that improve clinically important health outcomes. Several organizations have made recommendations regarding screening for CKD.
- Fink HA, Ishani A, Taylor BC, et al. Chronic Kidney Disease Stages 1–3: Screening, Monitoring, and Treatment. Comparative Effectiveness Review No. 37 (Prepared by the Minnesota Evidence-based Practice Center under Contract No. HHSA 290-2007-10064-I). Rockville, MD: Agency for Healthcare Research and Quality; January 2012. AHRQ Publication No. 11(12)-EHC075-EF. Available at www.effectivehealthcare.ahrq.gov/ckd.cfm.
Your slide tray is being processed.